Xcout IntelSign inSubscribe

Bausch & Lomb competitors & alternatives

HealthcareUnited States

The 12 closest competitors and alternatives to Bausch & Lomb among healthcare companies — ranked by similarity to what Bausch & Lomb actually does, not by market-cap band.

12Competitors listed

Subscribe to see Bausch & Lomb’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

About Bausch & Lomb

Bausch & Lomb is a major Canadian eye health products company based in Vaughan, Ontario. The firm operates globally as one of the world's largest suppliers of contact lenses, intraocular lenses, and comprehensive eye care pharmaceuticals.

Bausch & Lomb at a glance

Bausch & Lomb is a healthcare company headquartered in United States. Its most recent funding round, Series A, raised $31M in August 2007. Xcout tracks 2 named people at Bausch & Lomb, including Brent Saunders (CEO).

Bausch & Lomb leadership

  • Brent SaundersCEO
  • Brent SaundersChairman

Bausch & Lomb funding rounds

Every round on record:

DateRoundAmountInvestors
Series A$31M1 named

Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →

Top 12 Bausch & Lomb competitors

Ranked by semantic similarity — how close each company is to Bausch & Lomb by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.

Bausch Health Companies Inc.BHC · PharmaceuticalsLaval, Canada
77% matchPublic

Pharmaceuticals

Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.

Market cap$1.8B
Employees20,300
Bausch Health Companies Inc. competitors & alternatives →
EyePoint, Inc.PharmaceuticalsWatertown, United States
60% match

Pharmaceuticals

EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.

Valuation—
Employees165
EyePoint, Inc. competitors & alternatives →

Analyze another company

Search any company we track to see its competitive set.

Or describe a company

Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.

See the full profile of Bausch & Lomb and its market

Funding, investors, tech stack, hiring signals, leadership and corporate events — for Bausch & Lomband every competitor above — in one live dashboard.

Subscribe to Xcout Intel →